Expression	B:C1171362
IRF	O
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	O
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	O
Era.	O
Non	O
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Expression	O
IRF	B:C1564741
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	O
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	O
Era.	O
Non	O
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Expression	O
IRF	O
/	O
MUM1	B:C0299544
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	O
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	O
Era.	O
Non	O
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Expression	O
IRF	O
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	B:C0079744
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	O
Era.	O
Non	O
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Expression	O
IRF	O
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	O
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	B:C4087148
Era.	O
Non	O
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Expression	O
IRF	O
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	O
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	O
Era.	O
Non	B:C0024305
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Expression	O
IRF	O
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	O
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	O
Era.	O
Non	O
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	B:C0079744
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Expression	O
IRF	O
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	O
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	O
Era.	O
Non	O
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	B:C0079744
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Expression	O
IRF	O
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three	O
-	O
year	O
Survival	O
of	O
Diffuse	O
Large	I:C0079744
B	I:C0079744
Cell	I:C0079744
Lymphoma	I:C0079744
in	O
the	O
Immunochemotherapy	O
Era.	O
Non	O
Hodgkin	I:C0024305
lymphoma	I:C0024305
-	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
(	O
Diffuse	O
large	I:C0079744
B	I:C0079744
cell	I:C0079744
lymphoma	I:C0079744
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	B:C0012634
.	O

Analysis	B:C0936012
and	O
understanding	O
of	O
a	O
wide	O
range	O
of	O
characteristics	O
of	O
the	O
disease	O
,	O
which	O
include	O
:	O
clinical	O
,	O
immunohistochemical	O
,	O
cytogenetic	O
and	O
molecular	O
characteristics	O
may	O
improve	O
treatment	O
results	O
.	O

Analysis	O
and	O
understanding	O
of	O
a	O
wide	O
range	O
of	O
characteristics	O
of	O
the	O
disease	O
,	O
which	O
include	O
:	O
clinical	O
,	O
immunohistochemical	O
,	O
cytogenetic	B:C4055168
and	O
molecular	O
characteristics	O
may	O
improve	O
treatment	O
results	O
.	O

Analysis	O
and	O
understanding	O
of	O
a	O
wide	O
range	O
of	O
characteristics	O
of	O
the	O
disease	O
,	O
which	O
include	O
:	O
clinical	O
,	O
immunohistochemical	O
,	O
cytogenetic	O
and	O
molecular	O
characteristics	O
may	O
improve	B:C0184511
treatment	O
results	O
.	O

achieving	O
the	O
estimated	O
three	O
-	O
year	O
survival	O
and	O
influence	O
of	O
IRF	B:C1564741
/	O
MUM1	O
expression	O
to	O
three	O
-	O
year	O
survival	O
.	O

achieving	O
the	O
estimated	O
three	O
-	O
year	O
survival	O
and	O
influence	O
of	O
IRF	O
/	O
MUM1	B:C0299544
expression	O
to	O
three	O
-	O
year	O
survival	O
.	O

achieving	O
the	O
estimated	O
three	O
-	O
year	O
survival	O
and	O
influence	O
of	O
IRF	O
/	O
MUM1	O
expression	B:C1171362
to	O
three	O
-	O
year	O
survival	O
.	O

The	O
study	B:C2603343
included	O
60	O
patients	O
de	O
novo	O
DLBCL	O
.	O

The	O
study	O
included	O
60	O
patients	O
de	O
novo	O
DLBCL	B:C0079744
.	O

Median	B:C2939193
follow	O
-	I:C0260832
up	I:C0260832
was	O
47	O
months	O
(	O
3	O
-	O
91	O
months	O
)	O
.	O

Median	O
follow	B:C0260832
-	I:C0260832
up	I:C0260832
was	O
47	O
months	O
(	O
3	O
-	O
91	O
months	O
)	O
.	O

To	O
determine	O
differentiation	B:C0003324
immunophenotype	O
antibodies	O
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	O
,	O
anti-Bcl	O
-	I:C0003241
6	I:C0003241
,	O
IRF	O
-	I:C0299544
4	I:C0299544
/	O
MUM1	O
,	O
CD	O
138	I:C1609943
.	O

To	O
determine	O
differentiation	O
immunophenotype	B:C0079611
antibodies	O
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	O
,	O
anti-Bcl	O
-	I:C0003241
6	I:C0003241
,	O
IRF	O
-	I:C0299544
4	I:C0299544
/	O
MUM1	O
,	O
CD	O
138	I:C1609943
.	O

To	O
determine	O
differentiation	O
immunophenotype	O
antibodies	B:C0003241
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	O
,	O
anti-Bcl	O
-	I:C0003241
6	I:C0003241
,	O
IRF	O
-	I:C0299544
4	I:C0299544
/	O
MUM1	O
,	O
CD	O
138	I:C1609943
.	O

To	O
determine	O
differentiation	O
immunophenotype	O
antibodies	O
those	O
were	O
used	O
anti-CD20	B:C3891557
,	O
anti-CD10	O
,	O
anti-Bcl	O
-	I:C0003241
6	I:C0003241
,	O
IRF	O
-	I:C0299544
4	I:C0299544
/	O
MUM1	O
,	O
CD	O
138	I:C1609943
.	O

To	O
determine	O
differentiation	O
immunophenotype	O
antibodies	O
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	B:C3900024
,	O
anti-Bcl	O
-	I:C0003241
6	I:C0003241
,	O
IRF	O
-	I:C0299544
4	I:C0299544
/	O
MUM1	O
,	O
CD	O
138	I:C1609943
.	O

To	O
determine	O
differentiation	O
immunophenotype	O
antibodies	O
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	O
,	O
anti-Bcl	B:C0003241
-	I:C0003241
6	I:C0003241
,	O
IRF	O
-	I:C0299544
4	I:C0299544
/	O
MUM1	O
,	O
CD	O
138	I:C1609943
.	O

To	O
determine	O
differentiation	O
immunophenotype	O
antibodies	O
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	O
,	O
anti-Bcl	O
-	I:C0003241
6	I:C0003241
,	O
IRF	B:C0299544
-	I:C0299544
4	I:C0299544
/	O
MUM1	O
,	O
CD	O
138	I:C1609943
.	O

To	O
determine	O
differentiation	O
immunophenotype	O
antibodies	O
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	O
,	O
anti-Bcl	O
-	I:C0003241
6	I:C0003241
,	O
IRF	O
-	I:C0299544
4	I:C0299544
/	O
MUM1	B:C0299544
,	O
CD	O
138	I:C1609943
.	O

To	O
determine	O
differentiation	O
immunophenotype	O
antibodies	O
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	O
,	O
anti-Bcl	O
-	I:C0003241
6	I:C0003241
,	O
IRF	O
-	I:C0299544
4	I:C0299544
/	O
MUM1	O
,	O
CD	B:C1609943
138	I:C1609943
.	O

Included	O
the	O
GCB	B:C1333295
type	I:C1333295
was	O
65	O
%	O
.	O

Impact	B:C1512894
prognostic	I:C1512894
index	I:C1512894
IPI	O
>2	O
GBC	O
vs	O
non	O
GBC	O
p=0,038	O
X	O
(	O
2	O
)	O
.	O

Impact	O
prognostic	I:C1512894
index	I:C1512894
IPI	B:C1512894
>2	O
GBC	O
vs	O
non	O
GBC	O
p=0,038	O
X	O
(	O
2	O
)	O
.	O

Impact	O
prognostic	I:C1512894
index	I:C1512894
IPI	O
>2	O
GBC	B:C1333295
vs	O
non	O
GBC	O
p=0,038	O
X	O
(	O
2	O
)	O
.	O

Impact	O
prognostic	I:C1512894
index	I:C1512894
IPI	O
>2	O
GBC	O
vs	O
non	B:C1513916
GBC	O
p=0,038	O
X	O
(	O
2	O
)	O
.	O

Impact	O
prognostic	I:C1512894
index	I:C1512894
IPI	O
>2	O
GBC	O
vs	O
non	O
GBC	B:C1333295
p=0,038	O
X	O
(	O
2	O
)	O
.	O

Statistically	O
significant	O
difference	O
was	O
confirmed	O
compared	O
to	O
the	O
IPI	B:C1512894
>	O
2	O
to	O
3	O
year	O
OS	O
p<0,0005	O
X	O
(	O
2	O
)	O
.	O

Significantly	O
longer	O
three	O
-	O
year	O
survival	O
was	O
provided	O
in	O
the	O
group	O
GCB	B:C1333295
36	O
(	O
92,3	O
%	O
)	O
vs.	O
non	O
GCB	O
8	O
(	O
38,1	O
%	O
)	O
p=0,003	O
X	O
(	O
2	O
)	O
.	O

Significantly	O
longer	O
three	O
-	O
year	O
survival	O
was	O
provided	O
in	O
the	O
group	O
GCB	O
36	O
(	O
92,3	O
%	O
)	O
vs.	O
non	O
GCB	B:C1333295
8	O
(	O
38,1	O
%	O
)	O
p=0,003	O
X	O
(	O
2	O
)	O
.	O

Clinical	O
and	O
immunohistochemical	O
factors	O
showed	O
a	O
significant	O
impact	O
to	O
three	O
-	O
year	O
survival	O
by	O
univariate	O
:	O
LDH	B:C0022917
p=0,005	O
,	O
MUM1	O
p=0,003	O
,	O
while	O
CD10	O
p=0,069	O
was	O
confirmed	O
on	O
the	O
level	O
of	O
borderline	O
impact	O
.	O

Clinical	O
and	O
immunohistochemical	O
factors	O
showed	O
a	O
significant	O
impact	O
to	O
three	O
-	O
year	O
survival	O
by	O
univariate	O
:	O
LDH	O
p=0,005	O
,	O
MUM1	B:C0299544
p=0,003	O
,	O
while	O
CD10	O
p=0,069	O
was	O
confirmed	O
on	O
the	O
level	O
of	O
borderline	O
impact	O
.	O

Clinical	O
and	O
immunohistochemical	O
factors	O
showed	O
a	O
significant	O
impact	O
to	O
three	O
-	O
year	O
survival	O
by	O
univariate	O
:	O
LDH	O
p=0,005	O
,	O
MUM1	O
p=0,003	O
,	O
while	O
CD10	B:C0025250
p=0,069	O
was	O
confirmed	O
on	O
the	O
level	O
of	O
borderline	O
impact	O
.	O

Using	O
multivariate	O
analysis	O
,	O
expression	B:C1171362
MUM1	O
has	O
the	O
greatest	O
impact	O
p<0.0005	O
OR=0.083	O
(	O
95	O
%	O
CI	O
0.23-0.303	O
)	O
on	O
the	O
disease	O
outcome	I:C0679250
-	O
three	O
-	O
year	O
survival	O
.	O

Using	O
multivariate	O
analysis	O
,	O
expression	O
MUM1	B:C0299544
has	O
the	O
greatest	O
impact	O
p<0.0005	O
OR=0.083	O
(	O
95	O
%	O
CI	O
0.23-0.303	O
)	O
on	O
the	O
disease	O
outcome	I:C0679250
-	O
three	O
-	O
year	O
survival	O
.	O

Using	O
multivariate	O
analysis	O
,	O
expression	O
MUM1	O
has	O
the	O
greatest	O
impact	O
p<0.0005	O
OR=0.083	O
(	O
95	O
%	O
CI	O
0.23-0.303	O
)	O
on	O
the	O
disease	B:C0679250
outcome	I:C0679250
-	O
three	O
-	O
year	O
survival	O
.	O

expression	B:C1171362
MUM1	O
>	O
25	O
%	O
has	O
the	O
greatest	O
impact	O
on	O
the	O
disease	O
outcome	I:C0679250
-	O
three	O
-	O
year	O
survival	O
.	O

expression	O
MUM1	B:C0299544
>	O
25	O
%	O
has	O
the	O
greatest	O
impact	O
on	O
the	O
disease	O
outcome	I:C0679250
-	O
three	O
-	O
year	O
survival	O
.	O

expression	O
MUM1	O
>	O
25	O
%	O
has	O
the	O
greatest	O
impact	O
on	O
the	O
disease	B:C0679250
outcome	I:C0679250
-	O
three	O
-	O
year	O
survival	O
.	O

